Health and Beauty

Asthma Gina Classification

Omalizumab May Be Stepped-Down or Withdrawn in Severe Allergic Asthma

Omalizumab can be safely withdrawn in more than one-third of patients with severe allergic asthma (SAA) who are classified as Global Initiative for Asthma (GINA) step V and receiving oral corticosteroids, according to the results of the recent single-center, open-label intervention OmaAlizumab Dose Reduction (OMADORE) study published in the British Journal of Clinical Pharmacology .

The objective of the OMADORE study was to evaluate the viability of a step-down protocol for omalizumab therapy in patients with SAA. A total of 35 patients with SAA who were treated for a minimum of 1 year with oral corticosteroid therapy (equivalent to a mean daily dose of methylprednisolone 4 mg) were enrolled in the study. To be eligible for the protocol, patients needed to have received omalizumab treatment for at least 1.5 years, have reached their lowest tolerated dose of oral corticosteroid, and have spirometry values greater than or equal to the values they had at baseline.